Form 8-K - Current report:
SEC Accession No. 0001140361-22-043937
Filing Date
2022-12-01
Accepted
2022-12-01 08:12:01
Documents
14
Period of Report
2022-12-01
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc10044960_8k.htm   iXBRL 8-K 36551
2 EXHIBIT 99.1 brhc10044960_ex99-1.htm EX-99.1 20434
  Complete submission text file 0001140361-22-043937.txt   246796

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA roiv-20221201.xsd EX-101.SCH 4370
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE roiv-20221201_def.xml EX-101.DEF 18159
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE roiv-20221201_lab.xml EX-101.LAB 28150
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE roiv-20221201_pre.xml EX-101.PRE 20401
8 EXTRACTED XBRL INSTANCE DOCUMENT brhc10044960_8k_htm.xml XML 6557
Mailing Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11
Business Address CLARENDON HOUSE, 2 CHURCH STREET HAMILTON HM11 D0 HM11 441-295-5950
Roivant Sciences Ltd. (Filer) CIK: 0001635088 (see all company filings)

EIN.: 981173944 | State of Incorp.: D0 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-40782 | Film No.: 221437409
SIC: 2834 Pharmaceutical Preparations